EICHOR
● Terminated
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Condition: Non-small Cell Lung Cancer · NSCLC · Sponsor: BeiGene
About this study
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (NSCLC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (218)
| Providence Medical Foundation St Jude Heritage Healthcare | Fullerton, California, United States | — |
| Valkyrie Clinical Trials | Los Angeles, California, United States | — |
| Ocala Oncology Center Pl Dba Florida Cancer Affiliates Ocala | Ocala, Florida, United States | — |
| Advent Health Cancer Institute | Orlando, Florida, United States | — |
| Goshen Center For Cancer Care | Goshen, Indiana, United States | — |
| Baptist Health Lexington | Lexington, Kentucky, United States | — |
| University Medical Center New Orleans West Jefferson Medical Center | New Orleans, Louisiana, United States | — |
| Metro Minnesota Community Oncology Research Consortium (Mmcorc) | Saint Paul, Minnesota, United States | — |
| West Penn Hospital | Pittsburgh, Pennsylvania, United States | — |
| Centro Medical Austral | Buenos Aires, Argentina | — |
| Centro Para La Atencion Del Paciente Oncologico (Caipo) | San Miguel de Tucumán, Argentina | — |
| Concord Repatriation General Hospital | Concord, New South Wales, Australia | — |
+ 206 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04746924